Skip to main content
. Author manuscript; available in PMC: 2023 Sep 18.
Published in final edited form as: Curr Eye Res. 2021 Mar 24;46(10):1525–1530. doi: 10.1080/02713683.2021.1899246

Figure 1.

Figure 1.

STC-1 reduces IOP in the dexamethasone-injected mouse. (a) Complete experiment displayed in a longitudinal fashion for Group 1 (PBS treatment) and Group 2 (STC-1 treatment). (b) At week 0, there was no difference in IOP between right and left eyes. IOP measurements at week 3 show confirmation of dexamethasone-injected steroid-induced ocular hypertension prior to treatment randomization. At experimental week 6, with topical PBS treatment in both groups, IOP remained higher in dexamethasone-injected mice compared to vehicle-injected mice. STC-1 treatment of vehicle-injected mice showed significantly lower IOP compared to PBS-treated, vehicle-injected mice. STC-1 treatment of dexamethasone-injected mice showed significantly lower IOP than PBS-treated, dexamethasone-injected mice. STC-1-treated, vehicle-injected mice showed no significant difference in IOP compared to STC-1-treated, dexamethasone-injected mice. At experimental week 9, with topical PBS treatment in both groups, IOP remained significantly higher in dexamethasone-injected mice compared to vehichle-injected mice. Vehicle-injected mice with no topical treatment showed no significant difference in IOP compared to PBS-treated vehicle injected mice. STC-1-treated, dexamethasone-injected mice showed significantly lower IOP compared to PBS-treated, dexamethasone-injected mice. STC-1-treated, dexamethasone-injected mice showed lower IOP compared to untreated, vehicle-injected mice. (c) Representative toluidine blue-stained sections of steroid-induced ocular hypertension mice were examined following treatment with PBS and STC-1. In both treatment groups, normal-appearing open angles (asterisk), iris (arrow), and ciliary body (chevron) were observed. *P < .05, **P < .005, ***P < .001. Error bars represent mean ± standard deviation.